tirzepatide for heart failure Effects of on circulatory overload and end-organ damage in with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial Tirzepatide bests semaglutide in patients

Patorno E, Htoo PT, Glynn RJ, Schneeweiss S, Wexler DJ, Pawar A, Bessette LG, Chin K, Everett BM, Kim SC

The trial involving more than 3500 participants with type 2 diabetes and chronic kidney disease from 28 countries including Australia, the USA and China found a small weekly dose of semaglutide reduced the risk of major kidney events by 24 per cent

The findings were presented by Dr Elizabeth McDonald, a professor of radiology at the University of Pennsylvania and a breast radiologist at the Abramson Cancer Center

FDA-Approved Alternatives Acamprosate [15] Second-line option Similar NNT to naltrexone (approximately 11) Major drawback: Requires 6-9 tablets daily High pill burden significantly impacts adherence More complex dosing for busy ED implementation Safe for patients with liver disease and opioid use disorder Disulfiram [18-21] Works as aversive agent, causing disulfiram reaction from accumulation of acetaldehyde, when combined with alcohol Recent RCTs show no significant benefit for reducing alcohol use Poor adherence due to fear of severe side effects Less likely to be prescribed in the ED, as naltrexone is a better option

Which peptide should a lupus researcher start with